Because of its strong anti-VEGFR activity, all antiangiogenic MKIs carry a risk of bleeding, presumably due to blood-vessel destabilization following decreased matrix deposition, as well as the loss of vascular integrity, resulting in blood vessel rupture and thrombocytopenia [9,50]. This evidence concerns the gene KDR and Thrombocytopenia.